AUMdb

Qhp Capital, L.P.

SEC-registered Private Fund Manager · Mid-sized ($1B–$10B) CRD 311710 · SEC file 801-120523 · Raleigh, NC · www.qhpcapital.com
☆ Save with Pro ADV data as of Mar 30, 2026
Regulatory AUM
$4.6B
Discretionary
$4.6B
Clients
15
Avg AUM / client
$305M
Accounts
15
Employees
25

AUM over time

$0 $4.6B
Dec 2020 Dec 2025

Annual snapshots from Form ADV filings · as of Mar 30, 2026

Who they serve

Client typeClientsAUM% of AUM
Pooled investment vehicles (non-investment companies) 15 $4.6B 100.0%

Private funds (9)

Reported in Form ADV Section 7.B.(1), filing of Sep 2024 · $3.1B combined gross assets

FundTypeDomicileGross assetsOwners
Nq Pe Project Kit, L.P. Private Equity Fund Cayman Islands $747M 33
Novaquest Private Equity Fund I, L.P. Private Equity Fund Cayman Islands $648M 30
Nq Pe Orange Co Invest, L.P. Private Equity Fund Delaware $544M 32
Novaquest Private Equity Fund Ii, Lp Private Equity Fund Delaware $534M 58
Qhp Milky Way Spv, L.P. Private Equity Fund Cayman Islands $219M 21
Nq Pe Project Colosseum Co Invest, L.P. Private Equity Fund Delaware $197M 30
Nq Pe White Co Invest, L.P. Private Equity Fund Delaware $101M 3
Nq Pe Project Stingray Co Invest, L.P. Private Equity Fund Cayman Islands $65.8M 9
Nq Pe Project Inca Rollover, L.P. Private Equity Fund Delaware $40.0M 30

People (7)

NameRole / titleCredentialsWith firm sinceOwnership
Gillings, Dennis, Barry Shareholder Nov 2010 (16y) ≈ 37.5% – 75% via Pharmabio Development Inc.
Davenport, Roger, Lavern Partner Dec 2020 (6y) 10% – 25%
Edwards, Jeffrey, Scott Partner Dec 2020 (6y) 10% – 25%
Poole, Edward, Ashton Partner Dec 2020 (6y) 10% – 25%
Sorensen, Michael, David Partner Dec 2020 (6y) 10% – 25%
Knox, Charles, Robert Chief Financial Officer Jan 2022 (5y) Less than 5%
Fornes, Christine, Jane Chief Compliance Officer Sep 2024 (2y) Less than 5%

Entity owners (Schedule A/B)

EntityTitle / statusSinceSch.Ownership
Pharmabio Development Inc. Partner Dec 2020 A 50% – 75%
Qhp Capital Gp, Llc General Partner Dec 2020 A Less than 5%
Pharmabio Development Inc. Member Dec 2020 B ≈ 0% – 3.75% via Qhp Capital Gp, Llc

Undisclosed: 0% – 10% of the firm is not attributable from the filed Schedule A bands.

Estimated effective ownership (look-through of filed bands):

  • Gillings, Dennis, Barry: 75% – 100% of Pharmabio Development Inc. × 50% – 75% direct ≈ 37.5% – 75% of the firm
  • Pharmabio Development Inc.: 50% – 75% of Qhp Capital Gp, Llc × 0% – 5% direct ≈ 0% – 3.75% of the firm

Roster from the IAPD representatives feed; ownership and acquisition dates from Form ADV Schedule A/B. "Since" is the earliest filed registration or acquisition date.

Private funds (9, $3.1B gross assets)

FundTypeGross assetsMin. investmentOwners
Nq Pe Project Kit, L.P. Private Equity Fund $747M $5.0M 33
Novaquest Private Equity Fund I, L.P. Private Equity Fund $648M $5.0M 30
Nq Pe Orange Co Invest, L.P. Private Equity Fund $544M $5.0M 32
Novaquest Private Equity Fund Ii, Lp Private Equity Fund $534M $5.0M 58
Qhp Milky Way Spv, L.P. Private Equity Fund $219M $50.0K 21
Nq Pe Project Colosseum Co Invest, L.P. Private Equity Fund $197M $100K 30
Nq Pe White Co Invest, L.P. Private Equity Fund $101M $5.0M 3
Nq Pe Project Stingray Co Invest, L.P. Private Equity Fund $65.8M $5.0M 9
Nq Pe Project Inca Rollover, L.P. Private Equity Fund $40.0M $5.0M 30

From Form ADV Section 7.B private fund reporting.

Documents (1 archived)

FormPeriodSize
Form ADV (full filing) 03/30/2026 4.75 MB View · PDF · Source ↗

Archived copies of the firm's regulatory filings, versioned by content hash.

Disciplinary disclosures

No disciplinary events reported on the firm's latest Form ADV filing.

How they charge

  • Percentage of assets under management
  • Other fees
  • CARRIED INTEREST

Services

  • Portfolio management for pooled investment vehicles

Custody

Firm reports it does not have custody of client funds or securities (Item 9.A).

No custodian data reported or mined yet.

Source

All data on this page comes from this firm's Form ADV filings, reproduced without modification. Latest filing: Mar 30, 2026.

View current Form ADV (SEC/IAPD) ↗